The news: Eli Lilly’s latest obesity drug candidate delivered around 30% weight loss in adults with obesity in late-stage study results reported this week.

• Patients with obesity or who were overweight and have knee osteoarthritis lost an average of 70 pounds, or 28.3% of their weight, at 80 weeks.
• Those with a higher body mass index (BMI) of 35 or higher lost an average of 85 pounds, or 30.3%, at 104 weeks.

Why it matters: Lilly’s retatrutide is another GLP-1 obesity therapy (in this case, a combination GLP-1, GIP, and glucagon). Its high rate of weight loss could expand treatment options for patients with severe obesity beyond surgery and currently approved GLP-1 drugs.

The retatrutide study results are similar to bariatric surgery, which delivers average total body weight loss of 25% to 35%. Meanwhile, Lilly and Novo Nordisk’s approved GLP-1 obesity injections, Zepbound and Wegovy, deliver 15% to 20% efficacy, while oral candidates such as the Wegovy pill and Founday range from 11% to 15%.

Implications for obesity drugmakers: Lilly’s latest candidate shows how the obesity market is stratifying. Rather than competing as similar GLP-1 weight loss drugs, therapies are beginning to target different patient groups, weight loss goals, treatment stages, and drug formats.

Obesity care is pushing toward tiered treatment models:

• Oral drugs are aimed at convenience and broader adoption.
• Injectable therapies are targeting moderate-to-higher weight loss.
• High-dose/efficacy GP-1s and surgeries are focused on severe obesity.

For the nearly 170 obesity drugs still in clinical trials, the changing market is creating opportunities for drugmakers to target different segments of the obesity market rather than competing for the same patients and treatment goals.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.